Harvard Bioscience (HBIO) Finished Goods (2011 - 2026)

Harvard Bioscience (HBIO) has reported Finished Goods for 16 consecutive years, with $5.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Finished Goods fell 3.34% year-over-year to $5.7 million in Q2 2026; TTM through Jun 2026 was $5.7 million, a 3.34% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, up 2.85% from the prior year.
• Finished Goods was $5.7 million for Q2 2026 at Harvard Bioscience, up from $5.5 million in the prior quarter.
• Over five years, Finished Goods peaked at $6.8 million in Q1 2022 and troughed at $4.8 million in Q3 2024.
• A 5-year average of $5.6 million and a median of $5.5 million in 2024 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods jumped 32.93% in 2022 and decreased 24.33% in 2023, its largest moves.
• Over 5 years, Finished Goods stood at $5.2 million in 2022, then retreated by 1.97% to $5.1 million in 2023, then grew by 1.99% to $5.2 million in 2024, then advanced by 2.85% to $5.4 million in 2025, then rose by 6.81% to $5.7 million in 2026.
• The last three Finished Goods figures came in at $5.7 million (Q2 2026), $5.5 million (Q1 2026), and $5.4 million (Q4 2025), per Business Quant data.